BRUCE S KLEIN, MD
Medical Practice at University Ave, Madison, WI

5093118, Mar 3, 1992

Sep 14, 1989

7/406999

Bruce S. Klein - Madison WI
Jeffrey M. Jones - Madison WI

Wisconsin Alumni Research Foundation - Madison WI

G01N 33532, C07K 1510

424 88

A cell wall protein of the fungus B. dermatitidis is isolated and purified. The protein is readily recognized by serum antibodies from animals having blastomycosis. The protein antigen can be labelled to provide an assay for detection of the disease, it can be used to stimulate specific lymphocyte response and thereby provide another assay for detection of the disease, it can be used to produce an immune response to B. dermatitidis, or it can be used to create antibodies to the protein.

2013016, Jun 27, 2013

Dec 19, 2012

13/720513

Bruce Klein - Madison WI, US
Theodore Brandhorst - Madison WI, US

C07K 14/37, G01N 33/68

435 792, 530413, 435 71, 435 711, 530350

Methods for obtaining highly pure native, recombinant or modified BAD-1 protein include the steps of culturing a population of microbes expressing BAD-1 protein in a culture medium, collecting the population of microbes from the culture medium, obtaining a BAD-1 protein-containing solution, and purifying the BAD-1 protein from the solution by combining the BAD-1 protein-containing solution with a nickel-chelating resin, washing the nickel-chelating resin to remove unbound matter, and eluting the BAD-1 protein from the nickel-chelating resin. Highly pure native BAD-1 protein may be used in diagnostic kits for detecting infections in animals.

5302530, Apr 12, 1994

Feb 16, 1993

8/021537

Bruce S. Klein - Madison WI
Laura H. Hogan - Madison WI
Jeffrey M. Jones - Madison WI

Wisconsin Alumni Research Association - Madison WI

C12N 1570

4353201

Disclosed herein is a c-DNA coding for an antigen of B. dermatitidis. The antigen can readily be expressed in quantity at high purity from the cDNA, and the antigen can then be used for assays for the disease. The unique sequence This invention was made with United States Government support awarded by the National Institute of Health (NIH), Grant Nos. AI-00905 and AI-31479. The United States Government has certain rights in this invention.

2011031, Dec 29, 2011

Apr 19, 2011

13/089704

Bruce Steven Klein - Madison WI, US
Brad Mark Tebbets - Madison WI, US

A01N 43/824, A61K 31/433, A61K 31/4196, A01N 43/08, A01N 43/78, A61P 31/10, A01P 3/00, C07D 307/72, C07D 417/12, A61K 31/427, A61K 31/345, A01N 43/653

514363, 514472, 514383, 549481, 548142, 548183, 514369

A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is compound 13 or 33 and is combined with an azole compound, such as fluconazole.

6248322, Jun 19, 2001

Apr 17, 2000

9/551167

Bruce S. Klein - Madison WI
Theodore T. Brandhorst - Madison WI
Marcel Wuthrich - Madison WI

Wisconsin Alumni Research Foundation - Madison WI

A01N 6304

424 935

Disclosed herein are attenuated forms of the B. dermatitidis fungus. The fungus remains replication competent but is unable to express the WI-1 protein. One can administer this fungus to a dog, human, or other mammal to vaccinate them against the wild type fungus. Preferably, the administration is by subcutaneous injection.

7888120, Feb 15, 2011

Apr 12, 2007

11/734576

Bruce S. Klein - Madison WI, US
Julie C. Nemecek - Madison WI, US
Marcel Wuethrich - Madison WI, US

Wisconsin Alumni Research Foundation - Madison WI

C12N 15/00

435440, 435455

A method of screening a compound for anti-fungal properties comprising the steps of exposing a test compound to a fungal histidine kinase, and determining whether kinase activity is inhibited, wherein inhibition of kinase activity indicates that the compound has anti-fungal properties is disclosed.